Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2019; 11(6): 287-295
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.287
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.287
Hepatocellular carcinoma – time to take the ticket
Anju Mullath, Department of Gastroenterology, Lakeshore Hospital and Research Centre, Kochi 682040, Kerala, India
Murali Krishna, Department of Surgery, Military Hospital, Palampur 176061, Himachal Pradesh, India
Author contributions: Mullath A and Krishna M contributed equally to this work; Mullath A came up with the idea and performed the literature search; Krishna M wrote the manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Murali Krishna, DNB, MBBS, MD, Assistant Professor, Surgeon, Surgical Specialist, Department of Surgery, Military Hospital, Holta Camp, Palampur 176061, Himachal Pradesh, India. murali276@yahoo.com
Telephone: 91-841-1066008
Received: May 9, 2019
Peer-review started: May 10, 2019
First decision: May 31, 2019
Revised: June 13, 2019
Accepted: June 20, 2019
Article in press: June 21, 2019
Published online: June 27, 2019
Peer-review started: May 10, 2019
First decision: May 31, 2019
Revised: June 13, 2019
Accepted: June 20, 2019
Article in press: June 21, 2019
Published online: June 27, 2019
Core Tip
Core tip: The Milan criteria have been used extensively worldwide to select patients with hepatocellular carcinoma for liver transplantation. Over the years, it has been questioned whether the Milan criteria are too restrictive and whether patients outside the Milan criteria could benefit from liver transplantation. Several other criteria have been proposed and validated, and latest is the hepatocellular carcinoma Metroticket concept. This minireview evaluates the various current criteria that exist for liver transplantation for hepatocellular carcinoma cases.